Plasmacytoma – A Comprehensive Look into the Main Myeloma Cause
Plasmacytoma is considered to be the main reason for the development of myeloma conditions. Though a damaging disease on its own, an untreated condition will likely increase the danger of developing multiple myeloma tumors exponentially. Another “accessory” to this tumor can be paraproteinemia, which is an excess in the production and storage of a single monoclonal gamma globulin in the blood.
Plasmacytoma plays an important role in the development of monoclonal antibodies derived from artificial cells. Plasmacytoma is a tumor that can lend its multiplicative capabilities to several artificial antibodies. The first successful combining of plasmacytoma cells with an infusion of lymphocytes was achieved in 1975 by researchers Milstein and Kohler.
The experiment revolved around injecting a mouse with dinitrophenol 2.4 and fusing the resulting lymphocytes to cells from plasmacytoma. The resulting hybrid cell was producing an antibody to dinitrophenol 2.4 and was self replicating, just like the plasmacytomic cells were.
The development of monoclonal antibodies was a milestone in producing antibodies to counter various substances, with the virtual possibility to create antibodies to any substance. Among the benefits of this method, we number the possibility to gain an assertion to a wide array of chemical antibody inducements, as well a means to test for substances that were harder to detect in the bloodstream.
The most obvious result was the ability to detect antigens specific to certain types of viral infections and even antibodies specific to certain autoimmune diseases.
Plasmacytoma itself is a malignant tumor of the plasma cell, found in soft tissues or inside the bone structure. Such a tumor, when it exists in the skeleton, will most likely surround itself with various other forms of tumors and will often disseminate into multiple myeloma within a decade or so. It is usually diagnosed via serum protein electrophoresis and biopsy performed on the bone marrow. As a growth in the soft tissue, this tumor stands to affect tendons, fascia, fibrous tissues, fat, ligaments and synovial membranes. Due to the fact that the soft tissue is found around most of all major organs, any growth/abnormal behavior is likely to upset their functioning.
As to the treatment of such a tumor, the most frequently used method is local radiotherapy and this has been the most successful technique so far. More than 80% of the patients manage to have their tumor controlled locally and only 10% of them suffer any tumor reoccurrence.
The alternative is chemotherapy, reserved to patients that are unresponsive to regular radiotherapy. Also, in the case of neural impairment, surgery may become necessary to remove/reduce the tumor, though it is reserved as a last resort in the case of bone tumors.
Understanding plasmatic tumors is a matter of understanding cell biology. At a rate of millions per second, cells commit what we may call “suicide” in a human body. This functions as part of the normal replacement of cell structure. It also serves to keep a disease in check, as a cell that experiences mutation will automatically enter a process of self-destruction. If this does not happen, a diseased cell will multiply until it will reach a tumor phase. A benign malformation is harmless, but the growth of diseased cell could be cancerous. Studying the causes of cellular destruction is an important part in understanding the development of cancer.
Within the cell itself, a great deal of physical processes are observed throughout its lifespan. Cells follow a self-building architecture, called tensegrity, which protects them against mechanical tear caused by blood pressure, for example. Tensegrity evenly distributes any mounting pressure to the cytoskeleton and to other cellular components.
The key to understanding tumors is to consider them as abnormal body behavior or haywire cellular behavior. Unlike our common understanding of illnesses, the causes for tumors are embedded in our genetic code and are often the result of inadequate genetic adaptation to the exposure of modern day chemistry.
A tumor is not a dying piece of the patient, but rather a growing part. Such unusual behavior is a prime concern for geneticists, and treatments are being developed as we speak, to better understand and counteract it.
As a plasmatic tumor, plasmacytoma proves that tumors still hold various puzzles embedded in themselves.